#None #Northridge #Board of Directors #Diabetes Technology #MiniMed

MiniMed's New Leadership for a New Chapter

MiniMed, a prominent name in diabetes technology, has marked a significant milestone by announcing the establishment of its Board of Directors. This development follows the company's recent separation from Medtronic and signals a focused commitment to its mission: to improve the lives of those affected by diabetes.

A Vision for Independence

As it transitions into an independent entity, MiniMed is setting its sights on growth and innovation within the diabetes sector. The newly appointed Board boasts a wealth of expertise across various domains, including healthcare access, medical technology, and corporate governance. Their diverse backgrounds are expected to guide MiniMed in enhancing its offerings and accessibility for diabetes patients.

Kevin E. Lofton, former CEO of CommonSpirit Health, is appointed as the Chair of the Board. His extensive experience in leading significant healthcare systems will be pivotal as MiniMed navigates its future. Alongside him, Amy Bricker and Tim L. Main join the Board, bringing their own expertise in pharmacy operations and manufacturing, respectively. Their roles reaffirm the Board's focus on fostering innovative approaches to diabetes management.

Board Members' Expertise

The composition of the Board reflects MiniMed's strategic priorities, which include:

• - Kevin E. Lofton (Chair): A leader with nearly two decades at the helm of CommonSpirit Health, Lofton's career encompasses significant growth strategies and transformative leadership.
• - Que Dallara (CEO): Taking on the role of CEO in March 2026, Dallara's background in both Medtronic and Honeywell positions her to leverage technology in improving diabetes care.
• - Amy Bricker: With a robust track record in pharmacy management at Walgreens and Express Scripts, Bricker's insights into consumer healthcare will be invaluable for MiniMed.
• - Timothy L. Main: Former CEO of Jabil, Main's experience in scaling businesses globally will benefit MiniMed's operational strategy as it seeks to expand its market footprint.

Goals and Aspirations

In outlining MiniMed's goals, CEO Que Dallara emphasized the need to reduce the burden of diabetes management by simplifying access to integrated technologies. The formation of this Board is a critical step toward that mission, promoting a collaborative and innovative approach that combines insulin delivery, glucose monitoring, and software tools.

The Board's responsibilities will encompass key areas such as technology execution, commercial operations, manufacturing, and governance. Each member’s unique expertise will provide the oversight and direction necessary for MiniMed to pursue its ambitious objectives, making the entire diabetes management process more user-friendly and efficient.

Looking Ahead

As MiniMed forges ahead as an independent company, the emphasis on innovation is evident. The newly constituted Board reflects a strategic alignment with the company's vision of creating accessible solutions for diabetes care. With their extensive background in healthcare and technology, the Board members are poised to lead MiniMed into a future focused on improving the day-to-day experiences of individuals living with diabetes.

MiniMed’s long history and commitment to advancing diabetes care technologies positions it favorably as it embarks on this new chapter. Patients and stakeholders alike can look forward to the innovative strategies the new leadership will implement to enhance diabetes management and patient engagement.

In conclusion, the establishment of the Board marks an important moment for MiniMed. With a clear vision and strong leadership, the company is ready to navigate the complexities of the diabetes landscape as an independent player in the industry. With technology at its core, MiniMed aspires to transform how diabetes care is delivered, truly making every day a better day for patients around the globe.